RT Journal Article
SR Electronic
T1 Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 533
OP 546
DO 10.1124/mol.64.3.533
VO 64
IS 3
A1 Donald H. Maurice
A1 Daniel Palmer
A1 Douglas G. Tilley
A1 Heather A. Dunkerley
A1 Stuart J. Netherton
A1 Daniel R. Raymond
A1 Hisham S. Elbatarny
A1 Sandra L. Jimmo
YR 2003
UL http://molpharm.aspetjournals.org/content/64/3/533.abstract
AB Cyclic AMP (cAMP) and cGMP regulate a myriad of cellular functions, such as metabolism, contractility, motility, and transcription in virtually all cell types, including those of the cardiovascular system. Considerable effort over the last 20 years has allowed identification of the cellular components involved in the synthesis of cyclic nucleotides, as well as effectors of cyclic nucleotide-mediated signaling. More recently, a central role for cyclic nucleotide phosphodiesterase (PDE) has also been elaborated in many cell types, including those involved in regulating the activities of the cardiovascular system. In this review, we introduce the PDE families whose members are expressed in cells of the cardiovascular system including cardiomyocytes, vascular smooth muscle cells, and vascular endothelial cells. Because cell behavior is a dynamic process influenced by numerous factors, we will attempt to emphasize how changes in the activity, expression, and targeting of PDE influence cyclic nucleotide-mediated regulation of the behavior of these cells.